Tags

Type your tag names separated by a space and hit enter

Genetic engineering of live attenuated influenza viruses.
Methods Mol Biol. 2012; 865:163-74.MM

Abstract

The first live attenuated influenza vaccine (LAIV) was licensed in the USA in 2003; it is a trivalent vaccine composed of two type A (H1N1 and H3N2) and one type B influenza virus each at 10(7) fluorescent focus units (FFU). Each influenza vaccine strain is a reassortant virus that contains the hemagglutinin (HA) and neuraminidase (NA) gene segments from a wild-type influenza virus and the six internal protein gene segments from a master donor virus (MDV) of either cold-adapted A/Ann Arbor/6/60 or B/Ann Arbor/1/66. MDV confers the cold-adapted, temperature-sensitive, and attenuation phenotypes to the vaccine strains. The reassortant vaccine seeds are currently produced by reverse genetics and amplified in specific pathogen-free (SPF) 9-11 days old embryonated chicken eggs for manufacture. In addition, MDCK cell culture manufacture processes have been developed to produce LAIV for research use and with modifications for clinical and/or commercial grade material production.

Authors+Show Affiliations

MedImmune, Mountain View, CA, USA. jinh@medimmune.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22528159

Citation

Jin, Hong, et al. "Genetic Engineering of Live Attenuated Influenza Viruses." Methods in Molecular Biology (Clifton, N.J.), vol. 865, 2012, pp. 163-74.
Jin H, Chen Z, Liu J, et al. Genetic engineering of live attenuated influenza viruses. Methods Mol Biol. 2012;865:163-74.
Jin, H., Chen, Z., Liu, J., & Kemble, G. (2012). Genetic engineering of live attenuated influenza viruses. Methods in Molecular Biology (Clifton, N.J.), 865, 163-74. https://doi.org/10.1007/978-1-61779-621-0_10
Jin H, et al. Genetic Engineering of Live Attenuated Influenza Viruses. Methods Mol Biol. 2012;865:163-74. PubMed PMID: 22528159.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Genetic engineering of live attenuated influenza viruses. AU - Jin,Hong, AU - Chen,Zhongying, AU - Liu,Jonathan, AU - Kemble,George, PY - 2012/4/25/entrez PY - 2012/4/25/pubmed PY - 2012/8/8/medline SP - 163 EP - 74 JF - Methods in molecular biology (Clifton, N.J.) JO - Methods Mol. Biol. VL - 865 N2 - The first live attenuated influenza vaccine (LAIV) was licensed in the USA in 2003; it is a trivalent vaccine composed of two type A (H1N1 and H3N2) and one type B influenza virus each at 10(7) fluorescent focus units (FFU). Each influenza vaccine strain is a reassortant virus that contains the hemagglutinin (HA) and neuraminidase (NA) gene segments from a wild-type influenza virus and the six internal protein gene segments from a master donor virus (MDV) of either cold-adapted A/Ann Arbor/6/60 or B/Ann Arbor/1/66. MDV confers the cold-adapted, temperature-sensitive, and attenuation phenotypes to the vaccine strains. The reassortant vaccine seeds are currently produced by reverse genetics and amplified in specific pathogen-free (SPF) 9-11 days old embryonated chicken eggs for manufacture. In addition, MDCK cell culture manufacture processes have been developed to produce LAIV for research use and with modifications for clinical and/or commercial grade material production. SN - 1940-6029 UR - https://www.unboundmedicine.com/medline/citation/22528159/Genetic_engineering_of_live_attenuated_influenza_viruses_ L2 - https://dx.doi.org/10.1007/978-1-61779-621-0_10 DB - PRIME DP - Unbound Medicine ER -